Low expression of developing brain homeobox 2 (Dbx2) may serve as a biomarker to predict poor prognosis in endometrial cancer

Xinlu Zhang; Yaping Wang; Shujun Zhao; Qiaohong Qin; Min Zhang; Yi Jiang; Hai Zhu; Hongyu Li

Low expression of developing brain homeobox 2 (Dbx2) may serve as a biomarker to predict poor prognosis in endometrial cancer

Am J Transl Res. 2021 May 15;13(5):4738-4748. eCollection 2021.

Authors

Xinlu Zhang¹, Yaping Wang¹, Shujun Zhao^{1

2}, Qiaohong Qin^{1

2}, Min Zhang¹, Yi Jiang¹, Hai Zhu¹, Hongyu Li^{1

2}

Affiliations

¹ Gynecologic Oncology, The Third Affiliated Hospital of Zhengzhou University Zhengzhou 450000, Henan, P. R. China.
² Zhengzhou Key Laboratory of Gynecological Oncology, The Third Affiliated Hospital of Zhengzhou University Zhengzhou 450000, Henan, P. R. China.

PMID: 34150054
PMCID: PMC8205784

Abstract

Objective: For investigating Dbx2's expression in endometrial cancer (EC) and its effect on prognosis of patients with EC.

Methods: A comparison was performed in the Cancer Genome Atlas (TCGA) database in terms of the expression profiling of EC and the survival data. To obtain differential expression genes (DEGs), Volcano plot and Venn analysis were adopted. DEGs function was performed by carrying out the GO annotation analysis (GO) and gene set enrichment analysis (GSEA). In clinical EC samples, PCR was applied to the verification of Dbx2's expression.

Results: Dbx2 was a downregulated expression in tumor tissues. Dbx2 can have a poor prognosis role in EC by regulating the apoptotic signaling pathway and the immune pathway. Lower expression of Dbx2 was related to lymph node metastasis and FIGO stage.

Conclusion: Dbx2 is downregulated in endometrial cancer, which serves as a biomarker to predict poor prognosis.

Keywords: Dbx2; Endometrial cancer; bioinformatics analysis; biomarker; prognosis.